Medical Breakthrough Tested in Phase 2 and 3 Trials from Society of Urologic Oncology Clinical Trials Consortium
Due to the rapidly escalating health concerns and developments related to the global coronavirus (COVID-19), the AUA 2020 Annual Meeting in Washington, DC has been cancelled.
Thank you all for participating in the online vetting process for the SUO application for a Focused Practice Designation (FPD) in Urologic Oncology. The comments section provided much useful feedback regarding both support and areas of concern.
In 2018, the estimated number of new cases of urothelial bladder cancer (UC) in the United States was 81,000, with 17,240 estimated deaths. Comparable numbers from 2004 were approximately 64,000 and 12,000, respectively... Why has mortality from UC... remained unchanged for over 30 years?
This week, the Society of Urologic Oncology joined the American Urological Association, Bladder Cancer Advocacy Network, American Association of Clinical Urologists, LUGPA and Urology Care Foundation to express extreme concern about the shortage of TICE BCG and its effects on the care of patients with bladder cancer.
The American Joint Committee on Cancer (AJCC) has made available two important tools related to cancer staging on their website.
The role of genetic testing in prostate cancer is rapidly evolving. A substantial proportion of men with prostate cancer carry inherited genetic mutations in cancer risk genes, with estimates as high as 15% in men with metastatic castration resistant disease.
The American Board of Urology is beginning a new designation, called Focused Practice Designation (FPD). The purpose of the FPD is to recognize an area of sub-specialization within a specialty without the onerous need for the formal process of CAQ.
The Society of Urologic Oncology recently wrapped up another successful program at the 18th Annual Meeting. The Society saw its highest attendance yet with over 750 medical professionals present to learn about emerging medical techniques and engage in educational discussions. Meeting attendance is not the only thing on the rise, either, with membership in the Society nearing 1,000 members.
Durable responses in 35 percent of patients reported in Phase II data published in the Journal of Clinical Oncology
I am delighted on behalf of the editors and publisher of "Urologic Oncology: Seminars and Original Investigations" to share the exciting news of a dramatic increase in the journal's impact factor.
Three SUO members were honored at the SUO 2017 Annual Meeting at the AUA Saturday, May 13.
The Society of Urologic Oncology (SUO) endorses the American Urological Association’s comments about the United States Preventative Services Task Force’s (USPSTF’s) updated statement on PSA screening for prostate cancer.
Congratulations to Dr. John L. Gore, University of Washington, on his impressive second-place performance at the Early Career Investigators Showcase at the recent AUA meeting in San Diego, for his work entitled, "Patient-Centered Design and Implementation of Survivorship Tools for Men with Prostate Cancer".
Introducing the SUO Career Center